Updated:
Bone Health Technologies
Osteoboost is the first and only FDA-cleared wearable therapy for osteopenia—clinically proven to reduce bone loss in the spine. Order online with prescription.
Overview
Osteoboost is the first and only FDA-cleared wearable therapy for osteopenia—clinically proven to reduce bone loss in the spine. Order online with prescription.
General information
Firm type
Asset Manager
Location
Region
North America
Country
United States
City
Redwood City
Corporate office
Redwood City, CA, United States
Sector focus
Frequently asked questions
What does Bone Health Technologies do?
Bone Health Technologies commercializes Osteoboost, a prescription wearable device that uses precision vibration therapy to reduce bone density loss in postmenopausal women with osteopenia. The company's website states the device is FDA-cleared and clinically proven to slow loss of bone strength and density in the spine and hip.
Is Osteoboost FDA-cleared or FDA-approved?
Osteoboost is marketed as FDA-cleared, which is the regulatory pathway for Class II medical devices, not the more rigorous premarket approval (PMA) required for Class III devices like implantable bone stimulators. The company claims its device is the first FDA-cleared wearable therapy specifically for osteopenia.
Profile maintained by Altss. Updated: . To correct this record or make a privacy request, send the page URL and your evidence to privacy@altss.com; corrections are free.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: